About this trial
The objective of this study is to evaluate the impact of clinical decision support (CDS) in the form of an alert to identify patients who may be at risk of opioid use disorder (OUD) and a clinical care pathway helping providers treating patients with opioid use disorder. The pathway provides health care providers with information and suggestions for screening and treatment of opioid use disorder, including treatment with medications. The 2022 Centers for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends providers asses for and treat opioid use disorder using approved medications for opioid use disorder (MOUD). This project will randomize primary care providers at the clinic level to a control arm or intervention arm. The control arm will have access to the clinical care pathway, but will not be reminded to utilize the pathway when treating a patient with opioid use disorder. The intervention arm will receive a reminder nudge about the pathway. Buprenorphine (a medication used to treat opioid use disorder) prescribing behavior of providers and outcomes of patients will be examined based on medical records data collected during routine care. The study period will be approximately 18 months.
Eligibility criteria
Qualifiers
Primary care encounter AND
Current opioid prescription (not buprenorphine) and Active opioid medications over the last 90 days OR
Documented as on local Pain Registry "Does the patient fit the criteria to be included on the Pain Registry?" OR
Has active problem list diagnosis of long-term (current) use of opiate analgesic OR
Disqualifiers
Active cancer diagnosis in the last 1 year
Hospice care/palliative care order
Sickle cell disease diagnosis
Trial design
Treatments tested in this trial
- Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)
Treatment groups
Locations
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator